Pharmaceuticals

Acquired Autoimmune Hemolytic Anemia Market Forecast Assessing Growth Potential And Industry Direction

May 18, 2026May 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Acquired Autoimmune Hemolytic Anemia Market During The 2026–2030 Period?

The acquired autoimmune hemolytic anemia market size has experienced significant expansion in recent years. It is projected to increase from $2.14 billion in 2025 to $2.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. The factors contributing to its historical growth include improved autoimmune disease diagnosis, corticosteroid treatment reliance, hospital hematology specialization, an uptick in malignancy-linked anemia cases, and the availability of diagnostic tests.

The market size for acquired autoimmune hemolytic anemia is anticipated to experience significant expansion over the next few years. Its valuation is projected to reach $3.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period is attributable to rare disease awareness growth, biologic therapy adoption, advanced diagnostic integration, hematology research funding, and personalized treatment protocols. Furthermore, major trends in the forecast period include increasing use of targeted immunosuppressive therapies, rising adoption of rituximab-based treatment, growth in hospital-based hematology care, improved diagnostic testing adoption, and the expansion of rare disease treatment programs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp

Which Significant Factors Are Encouraging Growth In The Acquired Autoimmune Hemolytic Anemia Market?

The rising occurrence of autoimmune conditions is anticipated to fuel the expansion of the acquired autoimmune hemolytic anemia market in the future. Autoimmune disorders involve the immune system mistakenly attacking the body’s healthy cells and tissues, perceiving them as harmful invaders. This increasing prevalence of autoimmune disorders is primarily linked to more environmental triggers and shifts in lifestyle that can disrupt the immune system’s regulatory functions. Consequently, the growing number of autoimmune disorders leads to a higher frequency of acquired autoimmune hemolytic anemia, as individuals with such conditions are more prone to developing secondary AIHA due to their immune system dysregulation. For instance, in 2023, data from the Gastro-Intestinal Epidemiology Consortium (CanGIEC), a Canada-based national network of researchers and clinicians, indicated the prevalence of inflammatory bowel disease was estimated at 825 cases per 100,000 people. This figure is projected to increase by 2.44% annually, reaching 1,075 cases per 100,000 people by 2035. Thus, the escalating prevalence of autoimmune disorders will propel the growth of the acquired autoimmune hemolytic anemia market.

What Segment Categories Are Evaluated In The Acquired Autoimmune Hemolytic Anemia Market Study?

The acquired autoimmune hemolytic anemia market covered in this report is segmented –

1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test

2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab

3) By Severity: Mild, Moderate, Severe

4) By End User: Hospitals, Specialty Clinics, Research Institutions

Subsegments:

1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count

2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count

3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test

4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing

What Trends Are Affecting The Growth Of The Acquired Autoimmune Hemolytic Anemia Market?

Leading firms within the acquired autoimmune hemolytic anemia market are prioritizing breakthroughs in targeted treatments, like neonatal Fc receptor (FcRn) blockers, aiming to boost treatment effectiveness, better maternal and fetal health outcomes, and offer superior interventions for high-risk pregnancies affected by severe hemolytic disease. An FcRn blocker functions as a therapeutic antibody intended to block the neonatal Fc receptor, which typically recycles immunoglobulin G (IgG) antibodies in the body. This action consequently lowers harmful antibody levels that lead to the breakdown of red blood cells and hemolytic issues in both mothers and their fetuses. As an illustration, in January 2025, the US-based pharmaceutical and healthcare entity, Johnson & Johnson, was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for nipocalimab, intended for treating individuals with a high risk of severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab operates by precisely inhibiting the neonatal Fc receptor (FcRn), which decreases maternal IgG antibody concentrations that traverse the placenta and target fetal red blood cells. This effectively averts severe hemolytic disease, diminishes the requirement for intrauterine transfusions, and enhances results for high-risk pregnancies. This medication specifically addresses FcRn-driven IgG recycling, leaving other immune system functions undisturbed.

Who Are The Key Market Participants In The Acquired Autoimmune Hemolytic Anemia Market?

Major companies operating in the acquired autoimmune hemolytic anemia market are F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Novartis AG, Incyte Corporation, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Johnson & Johnson, Merck KGaA, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A.

Access The Complete Acquired Autoimmune Hemolytic Anemia Market Report:

https://www.thebusinessresearchcompany.com/report/acquired-autoimmune-hemolytic-anemia-global-market-report

Which Region Stands As The Largest Contributor To The Acquired Autoimmune Hemolytic Anemia Market?

North America was the largest region in the acquired autoimmune hemolytic anemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acquired Autoimmune Hemolytic Anemia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp

Browse Through More Reports Similar to the Global Acquired Autoimmune Hemolytic Anemia Market 2026, By The Business Research Company

Autoimmune Disease Diagnosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Autoimmune Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795